Cartesian Therapeutics Inc 's ability to collect accounts receivable sequentially worsen to 2.58, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Cartesian Therapeutics Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 141 days, from 126 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 560 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 3823 to 3832.

What is Receivable Turnover Ratio?
What is Cartesian Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RNAC Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-44.63 %	-85.21 %	27.87 %	-85.05 %	-98.9 %
Y / Y Revenue Change	-	-92.91 %	-	16.8 %	-99.11 %
Receivable Turnover Ratio (TTM)	2.58	2.9	2.83	1.18	0.52
RNAC's Total Ranking	# 3832	# 3823	# 3490	# 1637	# 3446
Accounts Receivable average collection period days	142	126	129	311	695
Seq. Receivable Change	-24.9 %	-76.59 %	54.43 %	103.95 %	-79.94 %
Seq. Revenue Change	-	-91.76 %	109.51 %	51.68 %	-72.91 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 199
Healthcare Sector	# 561
Overall Market	# 3832

Receivable Turnover Ratio Statistics
High	Average	Low
0.77	0.24	0
(Jun 30 2022)		(Dec 31 2017)

News about Cartesian Therapeutics Inc Receivables Turnover Ratios

Cartesian Therapeutics Begins Phase 1 Trial of Descartes-15 A Next-Generation mRNA CAR-T Therapy Achieving Br...

In a significant leap forward in the field of cancer therapy, Cartesian Therapeutics, a pioneering biotechnology firm specializing in the development of next-generation mRNA-based cell therapies, has announced that the first patient has been dosed in its first-in-human Phase 1 clinical trial evaluating Descartes-15, its novel mRNA CAR-T cell therapy. This milestone marks a crucial step in the company s mission to innovate cancer treatments that are more effective and safer for patients suffering from hematologic malignancies. Understanding CAR-T Cell Therapy Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the landscape of oncology, providing a personalized approach that harnesses the body’s immune system to fight cancer. Traditional CAR-T therapies have already made significant impacts in treating certain blood cancers, but they are often accompanied by adverse effects and limitations in efficacy.

RNAC Company Profile • Back to RNAC Efficiency Comparisons • Compare RNAC Receivables Turnover Ratio to its Competitors

Financial Statements
Cartesian Therapeutics Inc 's Accounts Receivable	$ 0 Millions	Visit RNAC's Balance sheet
Cartesian Therapeutics Inc 's Sales TTM	$ 1 Millions	Visit RNAC's Income Statement
Sources of RNAC's Revenues		Visit RNAC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RNAC's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RNAC's Growth Rates	RNAC's Roa	RNAC's Inventory Turnover Ratio	RNAC's Dividend Comparisons
RNAC's Profitability Ratios	RNAC's Roi	RNAC's Asset Turnover Ratio	RNAC's Dividend Growth
RNAC's Valuation Ratios	RNAC's Roe	RNAC's Financial Strength Ratios	RNAC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Lineage Cell Therapeutics Inc	20.02	$ 13.083 Millions	$ 0.654 Millions
Hims and Hers Health Inc	19.65	$ 2,578.494 Millions	$ 131.228 Millions
Neuraxis Inc	18.95	$ 5.316 Millions	$ 0.281 Millions
China Pharma Holdings Inc	18.55	$ 3.914 Millions	$ 0.211 Millions
Bausch Health Companies Inc	18.42	$ 10,853.000 Millions	$ 589.250 Millions
Arvinas Inc	17.26	$ 316.700 Millions	$ 18.350 Millions
Nrx Pharmaceuticals Inc	17.25	$ 3.394 Millions	$ 0.197 Millions
Polomar Health Services, Inc.	17.19	$ 3.172 Millions	$ 0.185 Millions
Anika Therapeutics Inc	16.70	$ 121.370 Millions	$ 7.266 Millions
Lifemd Inc	16.48	$ 163.363 Millions	$ 9.915 Millions
Longeveron Inc	16.43	$ 1.187 Millions	$ 0.072 Millions
Bioage Labs Inc	15.82	$ 10.355 Millions	$ 0.655 Millions
Vaxart Inc	15.09	$ 243.064 Millions	$ 16.108 Millions
Medicinova Inc	15.02	$ 0.920 Millions	$ 0.061 Millions
Voyager Therapeutics Inc	14.71	$ 34.459 Millions	$ 2.343 Millions
Halozyme Therapeutics Inc	14.68	$ 1,663.738 Millions	$ 113.332 Millions
Nexgel Inc	14.52	$ 11.810 Millions	$ 0.813 Millions
Skinhealth Systems Inc	14.42	$ 289.224 Millions	$ 20.051 Millions
Lftd Partners Inc	14.13	$ 35.335 Millions	$ 2.500 Millions
Talkspace Inc	14.09	$ 246.631 Millions	$ 17.506 Millions
Lifestance Health Group Inc	14.07	$ 1,584.834 Millions	$ 112.665 Millions
10x Genomics Inc	13.90	$ 616.566 Millions	$ 44.342 Millions
Amneal Pharmaceuticals Inc	13.90	$ 3,117.474 Millions	$ 224.342 Millions
Ataibeckley Inc	13.83	$ 4.473 Millions	$ 0.324 Millions
Corcept Therapeutics Inc	13.54	$ 830.813 Millions	$ 61.352 Millions
Rosecliff Acquisition Corp I	13.43	$ 16.467 Millions	$ 1.226 Millions
Precipio inc	13.25	$ 27.198 Millions	$ 2.052 Millions
Chemed Corporation	12.94	$ 2,595.001 Millions	$ 200.565 Millions
Qhslab Inc	12.77	$ 3.017 Millions	$ 0.236 Millions
Nrc Health	12.72	$ 139.996 Millions	$ 11.004 Millions

Date modified: 2026-09-26T07:30:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.